$LTRN (+2.9% pre) Lantern Pharma (LTRN) Receives FDA Authorization to Initiate its Phase 2 Clinical Trial, Harmonic™, for LP-300 in Never Smokers with Non-Small Cell Lung Cancer - SI   https://t.co/pxm1j0LUTn